

Funder	Project Title	Funding	Institution
Autism Speaks	Double-blind placebo controlled trial of subcutaneous methyl B12 on behavioral and metabolic measures in children with autism	\$150,000	University of California, Davis
Autism Speaks	Double masked placebo controlled trial of cholesterol in hypocholesterolemic ASD	\$300,000	Kennedy Krieger Institute
Autism Speaks	Neuronal nicotonic receptor modulation in the treatment of autism: A pilot trial of mecamlamine	\$58,000	The Ohio State University
Autism Speaks	A randomized, double blind, placebo controlled study of fatty acid supplementation in autism	\$140,000	Medical University of South Carolina
National Institutes of Health	Understanding repetitive behavior in autism	\$327,738	University of California, Los Angeles
National Institutes of Health	The pharmacogenetics of treatment for insistence sameness in autism	\$377,097	University of Illinois at Chicago
National Institutes of Health	Aripiprazole in children and adolescents with autistic disorder	\$1,338	Indiana University-Purdue University Indianapolis
National Institutes of Health	D-cycloserine in children and adolescents with autism	\$4,493	Indiana University-Purdue University Indianapolis
National Institutes of Health	Risperidone and behavior therapy in children and adolescents with pervasive disorder	\$3,446	Indiana University-Purdue University Indianapolis
National Institutes of Health	Intransal oxytocin in the treatment of autism	\$13,127	Mount Sinai School of Medicine
National Institutes of Health	Oxytocin vs placebo on response inhibition & face processing in autism	\$3,995	Mount Sinai School of Medicine
National Institutes of Health	Divalproex sodium ER in adult autism	\$1,142	Mount Sinai School of Medicine